Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Deferred Taxes (2016 - 2019)

Harvard Bioscience (HBIO) has disclosed Deferred Taxes for 10 consecutive years, with $42000.0 as the latest value for Q3 2019.

  • On a quarterly basis, Deferred Taxes fell 74.07% to $42000.0 in Q3 2019 year-over-year; TTM through Sep 2019 was -$2.9 million, a 90.12% decrease, with the full-year FY2018 number at -$2.9 million, down 80.62% from a year prior.
  • Deferred Taxes was $42000.0 for Q3 2019 at Harvard Bioscience, up from -$1000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $16.1 million in Q4 2015 to a low of -$2.9 million in Q4 2018.
  • A 5-year average of $745214.3 and a median of $1000.0 in 2015 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: plummeted 1019.05% in 2015, then skyrocketed 14933.33% in 2016.
  • Harvard Bioscience's Deferred Taxes stood at $16.1 million in 2015, then tumbled by 104.55% to -$734000.0 in 2016, then tumbled by 115.8% to -$1.6 million in 2017, then tumbled by 84.79% to -$2.9 million in 2018, then soared by 101.43% to $42000.0 in 2019.
  • Per Business Quant, the three most recent readings for HBIO's Deferred Taxes are $42000.0 (Q3 2019), -$1000.0 (Q1 2019), and -$2.9 million (Q4 2018).